The calcium antagonists (CA) which are at our disposal are a pharmacol
ogical class potentially active on the calcium homeostasis at the cent
ral nervous system level. Instead of reviewing the whole possibility o
f therapeutical potential targets, the authors review the 3 main possi
ble and up-to-date impacts of these compounds : cerebral vasoactivity,
neurotransmission, cell death. The actual lack of good clinical trial
s in those fields is stressed as well as the consequent necessity to s
timulate the undertaking of such trials in humans in order to avoid to
limit the use of GA in the only cardio-vascular spectrum.